drugset
drugset / Trial / NCT01564017

Dose-response Study With Subcutaneous Immunotherapy of an Standardized Dermatophagoides Pteronyssinus (DPT) Extract

NCT01564017 ↗

Phase 2 Completed 150 enrolled Roxall Medicina España S.A
RandomizedParallel-groupDouble-blindTreatment

Summary

As part of the registration plan of our products and after performing a Phase I study the present trial has been designed to compare the efficacy of 5 different doses of subcutaneous immunotherapy in depot presentation.

Timeline

Start
2012-05
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Allergovac Depot Vaccine 0.25 unknown Subcutaneous
Comparator Allergovac Depot Vaccine 0.5 unknown Subcutaneous
Comparator Allergovac Depot Vaccine 1 unknown Subcutaneous
Comparator Allergovac Depot Vaccine 2 unknown Subcutaneous
Comparator Allergovac Depot Vaccine 4 unknown Subcutaneous

Indications

allergic disease